Wellinks筹集1000万美元，扩大预测性心肺远程患者监测
Wellinks Raises $10M to Scale Predictive Cardiopulmonary Remote Patient Monitoring
需要了解的内容
总部位于New Haven的心肺数字健康服务提供商Wellinks已完成其B轮融资的首笔1000万美元资金募集。
本轮融资由战略合作伙伴
UMass Memorial Health领投，现有内部投资者参与。
Wellinks获FDA许可的Spire Remote Patient Monitoring（RPM）System及其专有的Health Tags，可对生理指标进行被动、连续追踪，在症状出现前最多提前一周预测临床恶化。
与UMass Chan Medical School联合开展的“Healthy at Home”研究所得的临床证据显示，参与者因COPD在30天内再次住院的几率降低了60%以上。
本轮资金将用于扩大商业覆盖范围，进入农村及医疗服务不足的市场；推进预测分析引擎；并将护理模式扩展至充血性心力衰竭（CHF）。
Wellinks持续预测性护理框架Wellinks已在其B轮融资首轮交割中筹集1000万美元，以在全国范围内扩大其虚拟护理和远程患者监测平台。本轮融资由长期商业合作伙伴UMass Memorial Health领投，现有风险投资者跟投，将推动公司拓展至充血性心力衰竭（CHF）领域，并支持更广泛的商业部署。
对于慢性阻塞性肺疾病（COPD）和CHF等慢性心肺疾病的管理，医疗系统仍面临持续挑战，导致可预防的30天内再次住院和急诊就诊率居高不下。传统护理模式通常依赖定期门诊就诊或患者手动自我报告，因此生理状况的恶化可能一直未被发现，直到急性症状需要紧急干预时才受到重视。
Wellinks通过将被动式可穿戴传感技术与预测分析相结合，解决这些护理缺口。该平台利用获FDA许可的Spire RPM system和专有的Health Tags，持续监测生理数据，在患者出现明显症状前最多提前7天检测到细微的生物标志物偏差。
在与UMass Chan Medical School联合开展的“Healthy at Home”研究中，通过Wellinks平台进行监测的COPD患者，与标准护理队列相比，30天内再次住院的几率降低了60%以上。在呼吸系统护理领域这些结果的基础上，Wellinks正利用新获得的资金，为高风险CHF人群调整其算法决策支持工具，并扩大面向专业医疗人员短缺的医疗服务不足地区和农村地区的服务可及性。
“我们与Wellinks的持续合作体现了双方对推进主动式、数据驱动护理的共同承诺，”UMass Memorial Health首席执行官Eric Dickson博士表示。“我们正在共同生成真实世界临床证据，为患者带来更好的结局，并为心肺护理的未来提供信息支持。”
What You Should Know
New Haven-based cardiopulmonary digital health provider Wellinks closed a $10M first tranche of its Series B funding round.
The financing was led by strategic partner
UMass Memorial Health alongside participation from existing inside investors.
Wellinks’ FDA-cleared Spire Remote Patient Monitoring (RPM) System and proprietary Health Tags deliver passive, continuous physiological tracking to predict clinical deterioration up to one week before symptom onset.
Clinical evidence from the joint “ Healthy at Home ” study with UMass Chan Medical School showed participants experienced over 60% lower odds of 30-day hospital readmission for COPD.
Capital proceeds will fund commercial footprint expansion into rural/underserved markets, advance predictive analytics engines, and extend the care model into Congestive Heart Failure (CHF).
Wellinks Continuous Predictive Care Framework Wellinks has secured $10M in the first close of its Series B financing to expand its virtual care and remote patient monitoring platform nationwide. Led by long-time commercial partner UMass Memorial Health alongside existing venture investors, the funding will fuel the company’s expansion into congestive heart failure (CHF) and support broader commercial deployment.
Managing chronic cardiopulmonary conditions like Chronic Obstructive Pulmonary Disease (COPD) and CHF remains a persistent challenge for health systems, driving high rates of preventable 30-day hospital readmissions and emergency department visits. Traditional care models often rely on periodic office visits or manual patient self-reporting, allowing physiological decline to go unnoticed until acute symptoms require emergency intervention.
Wellinks addresses these care gaps by pairing passive wearable sensing technology with predictive analytics. The platform utilizes the FDA-cleared Spire RPM system and proprietary Health Tags to continuously monitor physiological data, detecting subtle biomarker deviations up to seven days before a patient experiences overt symptoms.
In a joint “ Healthy at Home ” study conducted with UMass Chan Medical School, COPD patients monitored through the Wellinks platform demonstrated over 60% lower odds of 30-day hospital readmissions compared to standard care cohorts. Building on these results in respiratory care, Wellinks is utilizing the new capital to adapt its algorithmic decision-support tools for high-risk CHF populations and expand access in underserved and rural areas facing specialist shortages.
“Our continued collaboration with Wellinks reflects a shared commitment to advancing proactive, data-driven care,” said Dr. Eric Dickson, CEO at UMass Memorial Health. “Together, we’re generating real-world clinical evidence that supports better outcomes for patients and informs the future of cardiopulmonary care.” Reader Interactions